Telomir names Dr. Itzchak Angel as Chief Scientific Advisor

MIAMI, FL - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a pre-clinical-stage company focused on longevity science, announced the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Dr. Angel, with his extensive background in pharmaceutical innovation, will guide the development of Telomir's lead product candidate, Telomir-1, aimed at lengthening DNA's telomere caps, a key element in aging.

Dr. Angel's career spans over four decades, marked by significant contributions to the pharmaceutical industry, including the development of Ambien and Uroxatral at Synthelabo, now part of Sanofi-Aventis. His expertise covers a range of therapeutic areas, and he has held leadership roles at multiple pharmaceutical companies, guiding drug candidates from conception to market.

In his new role, Dr. Angel will work with Telomir's senior management to expedite Telomir-1's pre-clinical and clinical paths, optimizing drug production and forming strategic partnerships. These efforts aim to streamline the regulatory approval process for Telomir-1 in both human and veterinary indications.

Telomir has recently gained attention following positive coverage of Telomir-1's effects in senior dogs, leading to plans to pursue regulatory applications for veterinary use alongside submissions for human clinical trials. Dr. Angel's focus will be on elucidating the molecular mechanisms of Telomir-1, with potential applications for rare aging-related diseases like progeria.

Progeria, characterized by accelerated aging in children due to a genetic mutation, is a potential target for Telomir-1, which has shown promise in pre-clinical testing to elongate telomeres. This focus could expedite the clinical trial process and bring the treatment to market more quickly.

Dr. Angel expressed his impression of Telomir-1's potential in aging, immune modulation, and regenerative medicine. Dr. Michael Roizen, Telomir's Special Advisor, also underscored the potential of Telomir-1 in supporting stem cell health and longevity.

Telomir Pharmaceuticals is committed to advancing Telomir-1, which remains in preclinical development and has not yet been tested in humans. The company's ultimate goal is to promote longevity and enhance the quality of life, but it is important to note that there is no assurance that Telomir-1 will proceed through development or receive FDA approval.

This news is based on a press release statement and contains forward-looking statements subject to risks and uncertainties. Telomir advises that the forward-looking statements, including anticipated benefits and timelines, are not guarantees of future performance and are subject to various factors.

In other recent news, Telomir Pharmaceuticals reported significant health improvements in two senior dogs treated with their novel small molecule, Telomir-1, suggesting potential benefits for age-related conditions. The company has also announced the appointment of Dr. Itzchak Angel as Chief Scientific Advisor and Michelle Yanez as the new Chief Financial Officer. Telomir-1, which is designed to lengthen telomeres, the protective caps of DNA, is currently being studied for its potential in treating progeria, a rare genetic disorder characterized by accelerated aging. The company is considering applying for orphan drug status to expedite the drug's approval process for human use and exploring the possibility of obtaining Minor Use and Minor Species (MUMS) designation for veterinary applications. Telomir Pharmaceuticals has initiated a key study on the safety of Telomir-1 in geriatric canines and partnered with Argenta to conduct a study evaluating Telomir-1's efficacy in addressing canine osteoarthritis. These are among the recent developments at Telomir Pharmaceuticals.

InvestingPro Insights

As Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) advances its preclinical lead product candidate, Telomir-1, the company's financial health and market performance provide valuable context for potential investors. According to recent data from InvestingPro, Telomir has a market capitalization of $146.86 million, reflecting the market's current valuation of the company. Despite the challenges of not being profitable over the last twelve months, the company has demonstrated resilience with a strong return over the last month, showcasing a 48.5% price total return. This could indicate growing investor confidence in Telomir's potential, possibly bolstered by the appointment of Dr. Itzchak Angel and the positive outlook on Telomir-1.

An InvestingPro Tip highlights that Telomir operates with a moderate level of debt, which may provide the company with the financial flexibility needed to navigate the costly process of drug development and clinical trials. Moreover, the company's liquid assets exceed its short-term obligations, suggesting a stable financial position to support ongoing research and development efforts.

InvestingPro also notes that Telomir is trading at a high Price/Book multiple of 93.69, indicating that investors may be pricing in the high potential growth and future prospects of the company's innovative approach to longevity science. It's worth noting that the InvestingPro product includes additional tips for investors considering Telomir Pharmaceuticals, with a total of six more tips available that could further inform investment decisions.

For those interested in a more comprehensive analysis, additional InvestingPro Tips for Telomir Pharmaceuticals can be found at: https://www.investing.com/pro/TELO

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.